Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<i>Fusobacterium nucleatum-</i>derived succinic acid aggravates colitis by triggering macrophage pro-inflammatory phenotypic transformation via SUCNR1/NF-κB axis.

Gut microbes·2026

Same author

Job Crafting Through the Lens of Paradoxical Leadership: The Role of Positive Psychological Capital and Promotive Voice.

Behavioral sciences (Basel, Switzerland)·2026

Same author

Development and internal validation of a nomogram for predicting short-term functional improvement after pharmacological treatment in severe symptomatic lumbar disk herniation.

Frontiers in medicine·2026

Same author

Decoupling pitch and angle of attack with a variable-incidence wing extends quadrotor flight endurance.

Scientific reports·2026

Same author

Reconceptualizing Aplastic Anemia-Seed, Worm, Soil.

Journal of clinical laboratory analysis·2026

Same author

PyMACS: A python-based automation suite for GROMACS molecular dynamics setup, simulation, and analysis.

European journal of medicinal chemistry·2026

Search research articles

Related Experiment Video

Updated: Jul 22, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning.

Beronica A Ocasio^1,2,3, Jiaming Hu^1,3, Vasileios Stathias^2,3

¹Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

Biorxiv : the Preprint Server for Biology

|November 28, 2024

Summary

This study introduces SensitivitySeq, a novel deep learning tool that predicts effective small molecule compounds and gene targets for cancer therapy. It utilizes big data to overcome challenges in precision oncology drug development.

Keywords:

AI cancer informatics cell sensitivity deep learning drug development drug screening precision oncology targeted therapies transcriptional signatures

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

Related Experiment Videos

Last Updated: Jul 22, 2026

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

Area of Science:

Bioinformatics
Computational Biology
Genomics

Background:

Cancer drug development faces challenges like tumor heterogeneity and drug resistance.
Traditional methods struggle to overcome these complexities in precision oncology.
Big data approaches are emerging to advance cancer research and therapeutic strategies.

Purpose of the Study:

To develop a novel bioinformatics tool for predicting efficacious small molecule compounds and gene dependencies in cancer.
To leverage deep learning and big data for improved cancer drug discovery.
To address limitations in current cancer therapeutic development.

Main Methods:

Developed deep learning architectures integrating curated, standardized, and diverse datasets.
Utilized perturbation and baseline transcriptional signatures for prediction.
Performed internal and prospective validation in prostate cancer cell lines.

Main Results:

Reported SensitivitySeq, a novel bioinformatics tool for *in silico* prioritization of drug candidates and gene targets.
Demonstrated the tool's ability to predict drug sensitivity using gene expression and perturbation-response signatures.
Achieved validation of the deep learning approach *in vitro*.

Conclusions:

SensitivitySeq offers a powerful new method for identifying targeted cancer therapies.
The tool enhances precision oncology by predicting drug efficacy and genetic dependencies.
This represents a significant advancement in applying supervised deep learning to cancer drug discovery.